Moderna's stock is on the upswing as it hits new highs, fueled by strategic developments and positive market sentiment.
Moderna Inc (NASDAQ:MRNA) is rising today, with shares gaining approximately 2.79% to close at CA$187.19. This positive momentum follows recent statements from CEO Stéphane Bancel, who emphasized that the company is evolving beyond its initial COVID-19 vaccine focus.
Advertisement
Moderna Inc
MRNA.US
MRNA.US
Moderna Inc
WealthAwesomeMarket cap
$72.70B
52W high
$192.31
52W low
$22.28
1W change
+25.06%
Beta
1.11
Analyst Price Targets
Based on 27 analysts covering MRNA · as of Sep 17, 2026
Wall Street analysts forecast MRNA stock price to fall 34.3% over the next 12 months.
Consensus
Hold3.22 / 5.00
Avg. Target
C$119.56
-34.3% Upside
Current Price
C$182.11
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRNA's historical volatility
30-Day Vol
315.8%
Annualized
90-Day Vol
219.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$217.71
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$193.28 | C$65.02 – C$574.55 |
| 60 trading days | C$205.13 | C$43.95 – C$957.55 |
| 90 trading days | C$217.71 | C$32.99 – C$1436.79 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are responding favorably to Moderna's broader vision and strategic initiatives, particularly its foray into AI-driven drug development, which could enhance its research and development capabilities.
Market Cap Reaches CA$72.7 Billion
With a market capitalization of CA$72.7 billion, Moderna's valuation reflects investor confidence in its potential beyond COVID-19 vaccines.
Bull case
The appointment of co-founder Bob Langer to an AI drug development advisory board shows Moderna's commitment to innovation and diversification. This move could open up new revenue streams and strengthen its position in the market.
Bear case
Despite these positive developments, Moderna still has a negative profit margin, and the company faces ongoing scrutiny regarding its valuation and future earnings potential.
CEO's Vision for the Future
Advertisement
CEO Stéphane Bancel's recent remarks highlighted Moderna's commitment to expanding its portfolio beyond COVID-19 vaccines. By positioning the company as a leader in mRNA technology for various therapeutic areas, Bancel aims to attract new investors and boost market confidence.
AI-Driven Drug Development Initiatives
The appointment of co-founder Bob Langer to the advisory board of Cellular Intelligence marks a significant step in Moderna's strategy to integrate AI into its drug development processes. This collaboration could lead to breakthroughs in neurology and other fields, enhancing the company's research capabilities.
Market Reaction and Future Outlook
Today's stock performance reflects a positive market reaction to Moderna's evolving narrative. However, investors remain cautious due to the company's ongoing financial challenges, including a negative profit margin. The upcoming clinical trials and R&D updates will be crucial in determining the stock's trajectory.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
